



Published in final edited form as:

*Acta Neuropathol.* 2019 September ; 138(3): 401–413. doi:10.1007/s00401-019-02031-x.

## Contact sport participation and chronic traumatic encephalopathy are associated with altered severity and distribution of cerebral amyloid angiopathy

Oliver J. Standring<sup>1,2</sup>, Jacob Friedberg<sup>1,2</sup>, Yorghos Tripodis<sup>4</sup>, Alicia S. Chua<sup>4</sup>, Jonathan D. Cherry<sup>1,2,3</sup>, Victor E. Alvarez<sup>1,2,3,5</sup>, Bertrand R. Huber<sup>1,2,3</sup>, Weiming Xia<sup>5</sup>, Jesse Mez<sup>1,3</sup>, Michael L. Alosco<sup>1,3</sup>, Raymond Nicks<sup>1,5</sup>, Ian Mahar<sup>1,3</sup>, Morgan J. Pothast<sup>1,2,5</sup>, Hannah M. Gardner<sup>2</sup>, Gaoyuan Meng<sup>2,5</sup>, Joseph N. Palmisano<sup>1,6</sup>, Brett M. Martin<sup>1,6</sup>, Brigid Dwyer<sup>3,7</sup>, Neil W. Kowall<sup>1,2,3</sup>, Robert C. Cantu<sup>1,8,9,10,11</sup>, Lee E. Goldstein<sup>1,12,13,14</sup>, Douglas I. Katz<sup>3,7</sup>, Robert A. Stern<sup>1,3,8,10</sup>, Ann C. McKee<sup>1,2,3,5,14</sup>, Thor D. Stein<sup>1,2,5,14</sup>

<sup>1</sup>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston MA 02118, USA

<sup>2</sup>VA Boston Healthcare System, Boston MA, 02130, USA

<sup>3</sup>Department of Neurology, Boston University School of Medicine, Boston MA, 20118, USA

<sup>4</sup>Department of Biostatistics, Boston University School of Public Health, Boston MA, 20118, USA

<sup>5</sup>Department of Veterans Affairs Medical Center, Bedford MA, 01730, USA

<sup>6</sup>Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health

<sup>7</sup>Braintree Rehabilitation Hospital, Braintree MA, 02118, USA

<sup>8</sup>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston MA, 20119, USA

<sup>9</sup>Concussion Legacy Foundation, Boston MA, 02115, USA

<sup>10</sup>Department of Neurosurgery, Boston University School of Medicine, Boston MA, 02118, USA

<sup>11</sup>Department of Neurosurgery, Emerson Hospital, Concord MA, 01742, USA

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <https://www.springer.com/aam-terms-v1>

**Address correspondence to:** Thor D. Stein, MD, PhD, 150 S. Huntington Avenue, Boston, MA 02130, Phone: 857-364-5612, tdstein@bu.edu.

**Publisher's Disclaimer:** This Author Accepted Manuscript is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

**Potential Conflicts of Interest:** Lee E. Goldstein is a paid consultant to Johnson & Johnson (New Brunswick, NJ) / Janssen Research & Development, LLC (Raritan, NJ) and Rebiscan, Inc. (Cambridge, MA). He has received funding from the WWE and Ivivi Health Sciences. Robert A. Stern has received research funding from the NFL, the NFL Players Association, and Avid Radiopharmaceuticals, Inc. (Philadelphia, PA, USA). He is a member of the Mackey-White Committee of the NFL Players Association. He is a paid consultant to Amaranthus BioScience Holdings, Inc. (San Francisco, CA, USA) and Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA). He receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, FL, USA), as well as compensation from expert legal opinion. He has also provided consultation for Biogen (Cambridge, MA). Robert C. Cantu is a paid consultant to the NFL Head Neck and Spine Committee, NOCSAE, and Concussion Legacy Foundation, and he receives royalties from book publications and compensation from expert legal opinion.

<sup>12</sup>Departments of Psychiatry, Ophthalmology, Boston University School of Medicine

<sup>13</sup>Departments of Biomedical, Electrical & Computer Engineering, Boston University College of Engineering

<sup>14</sup>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston MA, 02118, USA

## Abstract

Cerebral amyloid angiopathy (CAA) consists of beta-amyloid deposition in the walls of the cerebrovasculature and is commonly associated with Alzheimer's disease (AD). However, the association of CAA with repetitive head impacts (RHI) and with chronic traumatic encephalopathy (CTE) is unknown. We evaluated the relationship between RHI from contact sports participation, CTE, and CAA within a group of deceased contact sports athletes (n=357), a community-based cohort (n=209), and an AD cohort from Boston University AD Center (n=241). Unsupervised hierarchical cluster analysis demonstrated a unique cluster (n= 11) with increased CAA in the leptomeningeal vessels compared to the intracortical vessels (p<0.001) comprised of participants with significantly greater frequencies of CTE (7/11) and history of RHI. Overall, participants with CTE (n=251) had more prevalent (p<0.001) and severe (p=0.010) CAA within the frontal leptomeningeal vessels compared to intracortical vessels. Compared to those with AD, participants with CTE had more severe CAA in frontal than parietal lobes (p<0.001) and more severe CAA in leptomeningeal than intracortical vessels (p=0.002). The overall frequency of CAA in participants with CTE was low, and there was no significant association between contact sports participation and the presence of CAA. However, in those with CAA, a history of contact sports was associated with increased CAA severity in the frontal leptomeningeal vessels (OR=4.01, 95% CI: 2.52-6.38, p<0.001) adjusting for AD, APOE ε4 status, and age. Participants with CAA had increased levels of sulcal tau pathology and decreased levels of the synaptic marker PSD-95 (p's<0.05), and CAA was a predictor of dementia (OR=1.75, 95% CI: 1.02-2.99, p=0.043) adjusting for age, sex, and comorbid pathology. Overall, contact sports participation and CTE were associated with more severe frontal and leptomeningeal CAA, and CAA was independently associated with worse pathological and clinical outcomes.

## Keywords

chronic traumatic encephalopathy; Alzheimer's disease; cerebral amyloid angiopathy; repetitive head impacts; mild traumatic brain injury; American football

## Introduction

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) within the vessel walls of cerebral arteries, arterioles, and capillaries [10, 11]. CAA is common in older adults and has been reported in up to 98% of Alzheimer disease (AD) cases [5]. Increasing age and genetic factors impact CAA pathology such as the presence of the *apolipoprotein E (APOE) allele ε4* [11, 42, 44]. CAA is primarily found within leptomeningeal vessels and superficial intracortical vessels and is generally more common in the posterior cerebral cortex (parietal and occipital lobes) than the frontal lobes [4, 43, 53–

56]. Beta amyloid (A $\beta$ ) deposition in the blood vessel wall leads to progressive weakening and dysfunction of the vessel wall with of rupture and subsequent intracerebral hemorrhage (ICH). CAA is a leading cause of ICH in elderly individuals [3,26, 55]. Independent of other pathologies, CAA is associated with age as well as impaired cognitive function and dementia likely due to a combination of hemorrhage, ischemia, and synaptic damage [11, 27].

Recent studies have suggested an association between traumatic brain injury (TBI) and repetitive head impacts (RHI) and neurodegenerative diseases [1, 20, 39, 41]. RHI and contact sports participation, such as American football, boxing, and ice hockey, are associated with the development of chronic traumatic encephalopathy (CTE). In addition to concussions and severe TBI, head impacts in contact sports that do not result in clinical symptoms (subconcussive injury) may still result in neuronal injury [33, 51]. The total number of years of contact sport participation is associated with the pathological stage of CTE and with severity of tau pathology [2, 12, 34, 35, 38]. For American football players, head collisions predominantly involve the anterior aspect of the skull, and a recent analysis of a helmet-to-helmet collision in football predicted that the greatest strain occurs in the frontal convexities and at the depths of sulci [9, 17, 21]. This correlates with the anatomical areas affected earliest and most severely by tau pathology in CTE and may result in a more frontal distribution of other pathologies, including CAA [34, 49].

Previous studies examining single TBI have not shown a significant relationship to CAA [16, 30]. However, the relationship between RHI and the development of small vessel disease is largely unknown. Amateur football players were found to have blood brain barrier (BBB) dysintegrity by dynamic contrast-enhanced MRI analysis after a single season of play compared to non-contact sport athletes [61]. RHI may also predispose individuals to small vessel vascular pathology such as CAA.

We hypothesized that participants with CTE or a history of RHI would have an altered distribution of CAA as well as increased prevalence and severity of CAA. We also performed a hypothesis free approach to look at the distribution of CAA by using hierarchal clustering. Additionally, we hypothesized that CAA was associated with the presence of dementia independent of other pathologies, including CTE.

## Methods

A total of 807 autopsy participants were examined from three different study groups utilizing previously described procedures [1, 40]. The Understanding Neurological Injury and Traumatic Encephalopathy (UNITE) group consisted of 357 participants with a history of exposure to contact sports such as football, ice hockey, boxing, soccer, rugby, and martial arts at either the professional or amateur level [37]. For most brain donations, the next of kin contacted the brain bank to donate tissue at or near the time of death. The second cohort consisted of 241 participants from Boston University's Alzheimer's Disease Center (BUADC) with and without cognitive impairment who underwent annual cognitive evaluations using the National Alzheimer's Disease Coordinating Center (NACC) Uniform Data Set (UDS) protocol [32]. The third cohort consisted of 209 participants from the

Framingham Heart Study (FHS), a longitudinal, community-based study. Consents for brain donation and research participation were provided by donor next of kin. Institutional review boards from the Boston University Medical Center approved brain donation, post-mortem clinical record review, neuropathological evaluation, and clinical interviews with donor family members.

### Clinical assessment

For UNITE study participants, information pertaining to RHI history, athletic or military service history, history of cognitive, mood, and behavior changes, and clinical status prior to death were all collected via post-mortem interviews with informants through online surveys and review of medical records as described previously [37]. All interviews were performed by neurologists and neuropsychologists trained to assess for RHI exposure and neurodegenerative diseases. In addition, medical records were examined to provide a comprehensive determination of clinical symptoms. For the FHS participants, an athletic history assessment identical to UNITE was performed with the donor's next of kin [21]. Athletic history was not available for BU ADC participants. For all studies, the presence of dementia was determined in a subset of participants by a panel of clinicians after review of medical and study records. A diagnosis of dementia was determined based on modified Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria and included reported evidence of neurobehavioral dysfunction and functional impairment. All interviews were conducted independently and blinded to the results of neuropathological examination.

### Pathological assessment

Neuropathological assessment was performed following procedures and criteria previously established for the UNITE study [37, 58]. The neuropathological diagnosis for CTE was made using only pathologic criteria as established by the National Institute of Neurological Disorders and Stroke consensus [32, 35]. Alzheimer's disease was diagnosed based on the National Institute of Aging Reagan criteria and included intermediate or high probability [40]. CAA was assessed in four cortical regions: dorsolateral frontal (Brodmann area 6,8), superior temporal (BA 20,21,22), inferior parietal (BA 39,40), and calcarine (BA 17,18) cortices. CAA evaluation and scoring were performed as described by Vonsattel et al. on a semi-quantitative 0-3 scale determined by the extent of A $\beta$  deposition within a blood vessel using A $\beta$  immunohistochemistry [59]. If no A $\beta$ -positive vessels were seen within a given region it was given a score of 0. The presence of A $\beta$  within smooth muscle cells in a normal vessel was classified as mild CAA and given a score of 1. Replacement of the tunica media by A $\beta$  without evidence of hemorrhage was classified as moderate CAA and given a score of 2. Vessel wall deposition of A $\beta$  with evidence of blood leakage or vessel wall fragmentation was defined as severe CAA and given a score of 3 [59]. Examples of each CAA score are shown in Supplemental Figure 1. Leptomeningeal and intracortical vessels were scored separately. A global CAA severity score was determined using NIA-AA guidelines [40]. In brief, no CAA was scored as 0, mild CAA or scattered A $\beta$ -positive vessels = 1; moderate CAA in multiple brain regions = 2; severe CAA in widespread brain regions = 3.

## Immunohistochemistry

Tissue was fixed in periodate-lysine-paraformaldehyde, tissue blocks were paraffin-embedded, and sections were cut at 10µm for immunohistochemistry. Antigen retrieval for and Aβ was performed with formic acid treatment for two minutes. Sections were incubated overnight at 4°C with antibodies to phosphorylated PHF-tau (AT8; Pierce Endogen, Rockford IL; 1:2000) and Aβ (4G8; BioLegend, San Diego, CA; 1:100,000). Sections were washed three times with PBS (pH 7.4), and subsequently treated with biotinylated secondary antibody and labeled with a 3-amino-9-ethylcarbazol HRP substrate kit (Vector Laboratories). The sections were then counterstained with Gill's Hematoxylin (Vector Laboratories H-3401) and coverslipped using Permount mounting medium. For tau pathology quantification, slides immunostained for ptau (AT8) were scanned at 20× magnification with a Leica Aperio Scanscope (Leica Biosystems, Richmond, IL) as previously described [13]. ImageScope (Leica Biosystems) was used to highlight the gray matter at the bottom third of the sulcus. Leica's image analysis and automated counting software (Aperio positive pixel count, Version 9) was calibrated for staining intensity to detect AT8-immunoreactivity within the region of interest. Counts were normalized to the area measured and are presented as positive pixels per mm<sup>2</sup> within the sulcal depth.

## Biochemical pathology measurements

Frozen tissue homogenate was prepared using ice cold 5M Guanidine Hydrochloride in Tris-buffered saline (20 mM Tris-HCl, 150 mM NaCl, pH 7.4 TBS) as previously described [50]. The lysate was diluted with 1% Blocker A (Meso Scale Discovery (MSD), Rockville, MD, #R93BA-4) in wash buffer according to the assays for Aβ 1-40 and 1-42 (MSD #K15200E-2) and PSD-95 (MSD #K250QND). Standards with known concentrations were used for Aβ. For PSD-95, arbitrary values were assigned to a reference brain lysate, which was run as a standard curve with every plate. All standards and samples were run in duplicate. Sulfo-tag conjugated anti-mouse secondary antibody was used for signal detection by the MSD SECTOR Imager 2400. Measurements were made on participants with available tissue (No CTE/AD: No CAA, n=73, CAA, n=10; CTE: No CAA, n=59; CAA, n=36).

## APOE genotyping

DNA was extracted from brain tissue and APOE genotype determined using two single nucleotide polymorphisms (National Center for Biotechnology Information SNPs rs429358 and rs7412) as described previously [50].

## Statistical analysis

Statistical analysis was performed SPSS version 20.0 (IBM Corp, Armonk, NY), Prism v6 and v7 (GraphPad Software, La Jolla, CA), and SAS version 9.4 (SAS Institute Inc., Cary, NC). In order to determine interrater reliability for CAA scoring between the three rating pathologists (ACM, BRH, and TDS), three participants with each score (0-3) as determined by one pathologist were blindly rated by the other two pathologists and an intraclass correlation coefficient statistic was performed to determine consistency among raters. In order to cluster similar distributions of CAA according to individual semiquantitative scores

in selected regions, an unbiased hierarchical cluster analysis was performed using the unbiased cluster function in R-Studio 3.4.1 (The R Foundation for Statistical Computing). The dendrogram illustrates this clustering with participants on the same branch with similar distributions and those further away with increasingly dissimilar distributions. Mean differences by cluster were analyzed using a linear mixed effects model allowing for subject-specific and location-specific random effects. For the analysis of variation between subject groups and analysis of prevalence data, we used a chi-square test for proportions and ANOVA with Bonferroni correction for continuous variables. Age adjusted estimated marginal means were determined for immunoassay measurements of A $\beta$  and PSD-95. PSD-95 values that were outside 1.5 $\times$  the interquartile range were eliminated as outliers and included no CTE/AD with CAA (n=2), CTE without CAA (n=2), and CTE with CAA (n=1). Quantitative protein measurements and location severity were analyzed by 2-way ANOVA with Holm-Sidak correction for multiple comparisons (GraphPad Prism 8). The relationships between CAA, CTE, contact sports exposure, and dementia were analyzed using logistic regression (dementia or CAA as binary outcomes) or cumulative logit proportional odds (CAA severity as ordinal outcomes) using SPSS (v.24, IBM). In order to account for differences between autopsy groups, propensity scores based on age, AD, and APOE  $\epsilon$ 4 status for the exposed and unexposed group were calculated in SAS version 9.4 and logistic and ordinal regressions were weighted with the calculated propensity scores.

## RESULTS

### Participant groups

Participants were grouped based on the presence or absence of CTE or AD pathology. Pathologic groups differed in age, gender, and comorbid pathologies (Table 1). The CTE cohort was significantly younger than other cohorts, and the CTE & AD and the No CTE/No AD groups were younger than the AD group. The CTE and CTE & AD groups also had a higher composition of men than the other groups and were significantly more likely to have participated in contact sports. The prevalence of CAA was highest in the AD and CTE & AD groups. The interrater reliability for CAA scoring between raters was found to be intraclass correlation coefficient = 0.920 (95% CI: 0.834 – 0.962,  $p < 0.001$ ), which shows excellent agreement.

### Hierarchical clustering shows distinct CAA distribution groups

In order to determine patterns of CAA distribution in an unbiased manner, a hierarchical clustering algorithm grouped participants with CAA and without missing data (n=222) by severity of CAA within the leptomeningeal and intracortical vessels in the four cortical regions, resulting in four distinct clusters (Figure 1a). Further analysis of these clusters showed that both cluster 2 and cluster 4 had significantly more leptomeningeal than intracortical CAA with cluster 2 showing a dramatic predominance of CAA in the leptomeninges compared to the cortex (Figure 1b,  $p$ 's  $< 0.001$ ). The frequency of CTE was greatest in cluster 2: 64% of individuals in cluster 2 had CTE, and 100% had a history of contact sports participation ( $p$ 's  $< 0.001$ , Table 2, RHI data were missing in one participant). Cluster 2 did not include any individuals with exclusively AD and CAA, despite that pathology comprising 40.5% of the overall cohort. (Figure 1c, Table 2). Overall, CTE and a



history of RHI were overrepresented in cluster 2 which had a predominance of leptomenigeal CAA. However, the small sample size of cluster 2 (n=11) limits the conclusions that can be made from this analysis. We therefore next set out to directly test hypotheses about altered CAA with RHI and CTE.

### Distribution by pathology

We hypothesized that the distribution of CAA would be altered in CTE such that there would be greater involvement of the frontal lobe compared to an aging AD population. The unbiased hierarchical clustering analysis further suggested increased leptomenigeal disease in CTE. In participants with AD, intracortical ( $p < 0.001$ ) and leptomenigeal ( $p = 0.012$ ) CAA were more frequent in the parietal lobe compared to the frontal lobe (Figure 2a). In addition, CAA severity scores were significantly greater in the parietal lobe compared to the frontal lobe in AD (cortical  $p < 0.001$ ; leptomenigeal  $p = 0.006$ , Figure 2b). In AD, comparison of CAA between the leptomenigeal and intracortical vessels showed no differences in frequency and decreased CAA severity in the leptomeninges compared to the cortex. In contrast, the CTE group had increased CAA frequency in both the frontal and parietal leptomeninges (frontal  $p < 0.001$ , parietal  $p = 0.015$ ) and increased CAA severity score in the frontal leptomeninges compared to both frontal and parietal cortices ( $p$ 's = 0.010). There were no significant differences between the superior temporal and calcarine cortices in participants with CTE while participants with AD had significantly increased CAA severity in the superior temporal gyrus compared to the calcarine gyrus (Supplemental Figure 2). Subsequent analysis shows similar location distributions when analyzed by contact sports exposure history instead of pathology, such that participants with a history of contact sports, regardless of pathology, showed the same significant differences seen in the CTE group and those without a contact sports history demonstrated CAA frequency and severity similar to that of the AD group (data not shown). Direct comparison between CAA in AD and CTE further highlights the differences in distribution. The difference of CAA severity was determined for each participant between the frontal and parietal lobes (frontal-parietal). Participants with CTE had a significant increase in frontal-parietal CAA severity compared to those with AD in the leptomeninges ( $p < 0.001$ ) and trended towards an increase in the intracortical vessels ( $p = 0.052$ ; Figure 2c). Similarly, the difference in CAA severity between the leptomenigeal and intracortical vessels (leptomeninges-cortex; Figure 2d) showed a significant increase in leptomenigeal CAA in those with CTE compared to participants with AD in both the frontal and the parietal lobes ( $p$ 's = 0.002).

In order to test whether differences were also present between cohorts, we compared the FHS and UNITE groups (ADC was excluded due to almost unanimous CAA prevalence), adjusting for age, *APOE ε4*, and AD. Logistic regressions showed that compared to the FHS cohort, the UNITE group was less likely to develop CAA overall (OR = 0.49, 95% CI: 0.28-0.84,  $p = 0.010$ ), but was more likely to develop CAA in the frontal leptomeninges (OR = 2.12, 95% CI: 1.21-3.71,  $p = 0.009$ ).

### Contact sports participation and CAA severity

In order to test the relationship between contact sports participation and CAA in the frontal leptomeninges, logistic (CAA presence) and cumulative logit proportional odds (CAA

severity ordinal outcomes) were conducted controlling for age, *APOE ε4*, and AD in a pooled group of participants where contact sports history was ascertained from the FHS and UNITE studies. Due to differences in the groups used for this pooled analysis, we generated propensity scores by matching individuals by age, AD, and *APOE ε4* status. The sample size was 469 for these analyses due to missing data for *APOE* genotype. In order to distinguish effects for the presence of CAA (yes/no) versus the severity of CAA (1-3 severity score) we examined each separately. A logistic regression demonstrated that the presence of CAA in the frontal leptomeninges was not significantly associated with a history of contact sports participation (OR = 0.79, 95% CI: 0.60-1.04,  $p = 0.089$ ) when the model was weighted by the calculated propensity scores. However, within those participants with CAA, a weighted cumulative logit proportional odds model showed that a history of contact sports participation was associated with increased odds of more severe CAA in the frontal leptomeninges (OR = 4.01,  $p < 0.001$ , Table 3). Years of contact sports participation was also associated with increased odds of more severe CAA in the frontal leptomeninges (OR = 1.06 per year of play,  $p < 0.001$ ). Sensitivity analyses showed that adjusting for CTE stage gave similar results (contact sports play OR = 3.67, 95% CI: 1.72-7.82,  $p < 0.001$ ), suggesting that the association between contact sports and CAA severity is not due to increasing CTE severity.

### **CAA was associated with increased neurodegenerative proteins and decreased PSD-95 density**

We next quantified levels of  $A\beta_{1-40}$ ,  $A\beta_{1-42}$ , and PSD-95 in participants with and without CTE and with frozen tissue available (No CTE/AD:  $n = 183$ ; CTE:  $n = 95$ ; Figure 3). As expected,  $A\beta_{1-40}$ , a major component of the amyloid in CAA, was significantly increased in those with CAA within the CTE group when comparing age-adjusted means ( $p < 0.001$ , Figure 3a). In addition,  $A\beta_{1-42}$  was increased in participants with CAA with and without CTE ( $p$ 's = 0.037, Figure 3b). Age-adjusted AT8 density, a marker of tau burden, was significantly increased within the sulcus ( $p = 0.033$ ) in those with CTE and CAA as compared to only CTE (Figure 3c). Given this increased pathology in participants with CAA, we hypothesized that PSD-95 (a marker for synaptic density) would be decreased in those with CAA. In fact, the age-adjusted mean of PSD-95 density was significantly decreased in those with CAA compared to those without CAA with and without CTE ( $p$ 's  $< 0.05$ , Figure 3d). For PSD-95, mean values were similar, but less significant when outliers were included in the analysis (adjusted  $p = 0.072$ ).

### **Pathological associations with dementia**

We next tested the association of CAA with dementia adjusting for comorbid pathology. A logistic regression demonstrated that moderate to severe CAA was significantly associated with increased odds for ante-mortem dementia (OR 1.75,  $p = 0.043$ ) adjusting for age, sex, CTE stage (stages 0-IV), neocortical Lewy body disease (LBD), AD, and cohort (Table 4). A sensitivity analysis demonstrated a similar effect of CAA on dementia (OR 1.84, CI 1.04-3.26,  $p = 0.037$ ) when adjusting for the presence of cortical microinfarcts.



## Discussion

This study examined the relationships between neuropathological diagnoses, RHI exposure from contact sports participation, and CAA. Unbiased hierarchical cluster analysis showed a unique cluster of individuals with leptomeningeal dominant CAA, most of whom had CTE and all of whom had a history of contact sports participation. Subsequent analysis by pathology showed that those with CTE had more CAA in leptomeningeal vessels than in intracortical vessels and had greater involvement of the frontal lobe. In contrast, participants with AD showed more CAA in the parietal lobe compared to the frontal lobe in both leptomeningeal and intracortical vessels. Ordinal logistic regression analysis showed that a history of contact sports play was not significantly associated with the overall presence of CAA, but was associated with more severe CAA in the frontal leptomeninges, adjusting for age, APOE  $\epsilon 4$ , and AD. The presence of CAA, in turn, was associated with increased levels of neurodegenerative proteins, decreased levels of PSD-95, and the presence of dementia. Overall, contact sports participation did not appear to affect the risk of developing CAA, but did modulate the severity and distribution of CAA when present.

Accumulating evidence suggests that prolonged contact sports participation and exposure to RHI are associated with multiple neurodegenerative conditions [1, 34, 38, 39, 50, 60]. However, the role of RHI in the development of small vessel disease is largely unknown. Human post-mortem analyses of individuals exposed to a single TBI demonstrated disruption of the BBB by the presence of extravasated serum proteins in brain tissue, even years after the injury [24, 51] and similar results have been described in a case of CTE [19]. Another study found that A $\beta$  burden was increased in individuals with a history of TBI [47]. Animal models have shown an association between TBI and damage to the meningeal cerebrovascular, including intravascular leakage into the CSF after TBI [15, 31, 46] and marked disruption of the BBB following single and repetitive blast and concussion exposure [22, 51]. A study of two separate and pooled autopsy cohorts did not find an association between TBI with or without loss of consciousness and the presence of CAA [16]. However, the distribution and severity of CAA was not delineated in this study.

The distribution of CAA has been characterized in multiple aging populations, largely focusing on the topographical distribution between different cortical regions [4, 55, 56]. In AD, CAA predominates in the parietal and occipital lobes [4, 43, 53–56] and may favor the leptomeningeal over the intracortical vessels [4, 6]. We also found CAA significantly increased in the parietal lobe compared to the frontal lobe in AD. In contrast, CAA in the CTE group was more severe CAA in frontal than parietal lobes. Moreover, CAA in the RHI and CTE groups was predominantly leptomeningeal and did not appear to be related to the age at death. The leptomeningeal vessels may be particularly susceptible to tissue strain associated with RHI as they are tethered to the pia mater and travel within sulci [21]. Cortical capillary involvement by CAA is a distinct subtype that is related to APOE  $\epsilon 4$  [25, 52]. In addition, dysphoric CAA has been related to tau pathology [45]. Although CAA in participants with RHI and CTE predominantly involved the leptomeningeal vessels and dysphoric angiopathy was not a prominent feature, further study of capillary CAA and dysphoric angiopathy in association with RHI and CTE is warranted.

One functional consequence of CAA may be the loss of vessel elasticity and the subsequent inhibition of perivascular clearance of solutes out of the brain parenchyma into CSF [18, 23, 48, 62]. Thus, CAA may contribute to the buildup of both A $\beta$  and tau proteins within the brain parenchyma. We found that within participants with CTE, the presence of CAA was associated with significantly increased A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub>, sulcal tau pathology, and decreased PSD-95 (synaptic density marker) (Figure 3). Although CAA may precipitate tau accumulation via vessel dysfunction, it is also possible that tau accumulation may lead to vessel damage and subsequent CAA [36]. Future studies examining the temporal and spatial relationship between CAA and tau accumulation in CTE are necessary.

Consistent with the association between CAA and decreased PSD-95, CAA was a significant predictor of dementia even when adjusting for AD, LBD, CTE, and study group (Table 4). Similarly, a previous study showed that CAA significantly increased risk of AD dementia controlling for AD pathology such as plaques and tangles, suggesting an independent contribution to clinical dementia [8]. As CAA is associated with increased risk for spontaneous hemorrhage, dementia may be partially due to hemorrhagic tissue damage [7, 29]; however, CAA may also independently predict dementia as cognitive decline often precedes overt hemorrhage in subjects with CAA [14, 57]. Our findings show an association between CAA and dementia when adjusting for a history of microinfarcts supporting a role for other mechanisms in CAA-associated dementia such as persistent inflammation, vasoconstriction-related ischemia [28, 63], and decreased synaptic density.

### Limitations

There were several limitations to this study. Autopsy groups differed in composition and recruitment. Individuals in the UNITE group were largely self-selected or referred by the next-of-kin after death and do not represent all individuals who have a history of contact sports play. The FHS brain cohort is a subset of the larger FHS cohort, and although it is a community-based study population, autopsy-based selection bias was present as evidenced by high disease prevalence. Although the three cohorts were distinct, data was carefully harmonized. Neuropathological evaluation was performed for all three studies by the same experienced neuropathologists using standard research protocols, and dementia diagnoses were obtained by expert clinicians using established guidelines. Methods for determination of RHI exposure were standardized across FHS and UNITE; however, the data depended on retrospective review that might have introduced bias. In attempts to account for differences in age, sex, pathology, and autopsy group we adjusted for these variables when appropriate and performed a propensity analysis to appropriately group comparisons when testing for the association of contact sports participation on the development and severity of CAA. Future studies within larger community-based aging cohorts with RHI history as well as prospective studies will be necessary to confirm and expand these findings. Although we used PSD-95 as a marker for synaptic density, there are more precise ways to measure synaptic density such as electron microscopy and super-resolution microscopy, which warrant future study. In addition, the mechanisms underlying the putative vascular injury due to RHI remain to be elucidated.

## Conclusions

Both a history of contact sports participation and years of play were significantly associated with increased severity, but not frequency, of CAA in the frontal leptomeninges. In CTE, CAA was primarily leptomeningeal with increased involvement of the frontal relative to parietal cortex compared to participants with AD. Overall, RHI may alter the distribution and severity of CAA and thus lead to increased risk of dementia through multiple pathways.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENTS

This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (I01-CX001038); Veterans Affairs Biorepository (BX002466); Alzheimer's Association (NIRG-305779, NIRG-362697, AARF-17-529888); National Institute of Aging (RF1AG054156, R56AG057768, R01AG057768, K23AG046377, R01AG016495, R01AG033040, K23NS102399); National Institute of Neurological Disorders and Stroke (U01NS086659, F32NS096803, R01NS017950); National Institute of Aging Boston University AD Center (P30AG13846; supplement 0572063345-5); Department of Defense, Chronic Effects of Neurotrauma Consortium (CENC) Award W81XWH-13-2-0095 and Department of Veterans Affairs CENC Award I01-CX001135; National Heart, Lung, and Blood Institute, Framingham Heart Study (N01-HC-25195, HHSN268201500001I); Concussion Legacy Foundation. IM receives funding as a Fonds de Recherche du Québec - Santé (FRQS) postdoctoral scholar. This work was also supported by unrestricted gifts from the Andlinger Foundation and WWE. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We gratefully acknowledge the use of resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA), the outreach and recruitment contributions of Dr. Christopher Nowinski from the Concussion Legacy Foundation, and all the individuals whose participation and contributions made this work possible.

## References

1. Adams JW, Alvarez VE, Mez J, Huber BR, Tripodis Y, Xia W, Meng G, Kibilus CA, Cormier K, Kiernan PT et al. (2018) Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports. *J Neuropathol Exp Neurol* 77: 757–768 Doi 10.1093/jnen/nly065 [PubMed: 30053297]
2. Alosco ML, Mez J, Tripodis Y, Kiernan PT, Abdolmohammadi B, Murphy L, Kowall NW, Stein TD, Huber BR, Goldstein LE et al. (2018) Age of first exposure to tackle football and chronic traumatic encephalopathy. *Ann Neurol* 83: 886–901 Doi 10.1002/ana.25245 [PubMed: 29710395]
3. Attems J, Jellinger K, Thal DR, Van Nostrand W (2011) Review: sporadic cerebral amyloid angiopathy. *Neuropathol Appl Neurobiol* 37: 75–93 Doi 10.1111/j.1365-2990.2010.01137.x [PubMed: 20946241]
4. Attems J, Jellinger KA, Lintner F (2005) Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. *Acta Neuropathol* 110: 222–231 Doi 10.1007/s00401-005-1064-y [PubMed: 16133541]
5. Attems J, Lauda F, Jellinger KA (2008) Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy: an autopsy study. *J Neurol* 255: 70–76 Doi 10.1007/s00415-008-0674-4 [PubMed: 18202817]
6. Attems J, Quass M, Jellinger KA, Lintner F (2007) Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. *J Neurol Sci* 257: 49–55 Doi 10.1016/j.jns.2007.01.013 [PubMed: 17306303]
7. Biffi A, Greenberg SM (2011) Cerebral amyloid angiopathy: a systematic review. *J Clin Neurol* 7: 1–9 Doi 10.3988/jcn.2011.7.1.1 [PubMed: 21519520]

8. Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, Schneider JA (2015) Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. *Neurology* 85: 1930–1936 Doi 10.1212/WNL.0000000000002175 [PubMed: 26537052]
9. Broglio SP, Sosnoff JJ, Shin S, He X, Alcaraz C, Zimmerman J (2009) Head impacts during high school football: a biomechanical assessment. *J Athl Train* 44: 342–349 Doi 10.4085/1062-6050-44.4.342 [PubMed: 19593415]
10. Charidimou A, Boulouis G, Gurol ME, Ayata C, Bacskai BJ, Frosch MP, Viswanathan A, Greenberg SM (2017) Emerging concepts in sporadic cerebral amyloid angiopathy. *Brain* 140: 1829–1850 Doi 10.1093/brain/awx047 [PubMed: 28334869]
11. Charidimou A, Gang Q, Werring DJ (2012) Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. *J Neurol Neurosurg Psychiatry* 83: 124–137 Doi 10.1136/jnnp-2011-301308 [PubMed: 22056963]
12. Cherry JD, Mez J, Crary JF, Tripodis Y, Alvarez VE, Mahar I, Huber BR, Alosco ML, Nicks R, Abdolmohammadi Bet al. (2018) Variation in TMEM106B in chronic traumatic encephalopathy. *Acta Neuropathol Commun* 6: 115 Doi 10.1186/s40478-018-0619-9 [PubMed: 30390709]
13. Cherry JD, Tripodis Y, Alvarez VE, Huber B, Kiernan PT, Daneshvar DH, Mez J, Montenegro PH, Solomon TM, Alosco MLet al. (2016) Microglial neuroinflammation contributes to tauaccumulation in chronic traumatic encephalopathy. *Acta Neuropathol Commun* 4: 112 Doi 10.1186/s40478-016-0382-8 [PubMed: 27793189]
14. Cordonnier C, Leys D, Dumont F, Deramecourt V, Bordet R, Pasquier F, Henon H (2010) What are the causes of pre-existing dementia in patients with intracerebral haemorrhages? *Brain* 133: 3281–3289 Doi 10.1093/brain/awq246 [PubMed: 20852266]
15. Corps KN, Roth TL, McGavern DB (2015) Inflammation and neuroprotection in traumatic brain injury. *JAMA Neurol* 72: 355–362 Doi 10.1001/jamaneurol.2014.3558 [PubMed: 25599342]
16. Crane PK, Gibbons LE, Dams-O'Connor K, Trittschuh E, Leverenz JB, Keene CD, Sonnen J, Montine TJ, Bennett DA, Leurgans Set al. (2016) Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. *JAMA Neurol* 73: 1062–1069 Doi 10.1001/jamaneurol.2016.1948 [PubMed: 27400367]
17. Crisco JJ, Fiore R, Beckwith JG, Chu JJ, Brolinson PG, Duma S, McAllister TW, Duhaime AC, Greenwald RM (2010) Frequency and location of head impact exposures in individual collegiate football players. *J Athl Train* 45: 549–559 Doi 10.4085/1062-6050-45.6.549 [PubMed: 21062178]
18. Diem AK, Tan M, Bressloff NW, Hawkes C, Morris AW, Weller RO, Carare RO (2016) A Simulation Model of Periarterial Clearance of Amyloid-beta from the Brain. *Front Aging Neurosci* 8: 18 Doi 10.3389/fnagi.2016.00018 [PubMed: 26903861]
19. Farrell M, Aherne S, O'Riordan S, O'Keeffe E, Greene C, Campbell M (2019) Blood-brain barrier dysfunction in a boxer with chronic traumatic encephalopathy and schizophrenia. *Clin Neuropathol* 38: 51–58 Doi 10.5414/NP301130 [PubMed: 30574863]
20. Gardner RC, Burke JF, Nettiksimmons J, Kaup A, Barnes DE, Yaffe K (2014) Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. *JAMA Neurol* 71: 1490–1497 Doi 10.1001/jamaneurol.2014.2668 [PubMed: 25347255]
21. Ghajari M, Hellyer PJ, Sharp DJ (2017) Computational modelling of traumatic brain injury predicts the location of chronic traumatic encephalopathy pathology. *Brain* 140: 333–343 Doi 10.1093/brain/aww317 [PubMed: 28043957]
22. Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Upreti C, Kracht JM, Ericsson M, Wojnarowicz MWet al. (2012) Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. *Sci Transl Med* 4: 134ra60 Doi 10.1126/scitranslmed.3003716
23. Hawkes CA, Jayakody N, Johnston DA, Bechmann I, Carare RO (2014) Failure of perivascular drainage of beta-amyloid in cerebral amyloid angiopathy. *Brain Pathol* 24: 396–403 Doi 10.1111/bpa.12159 [PubMed: 24946077]
24. Hay JR, Johnson VE, Young AM, Smith DH, Stewart W (2015) Blood-Brain Barrier Disruption Is an Early Event That May Persist for Many Years After Traumatic Brain Injury in Humans. *J Neuropathol Exp Neurol* 74: 1147–1157 Doi 10.1097/NEN.0000000000000261 [PubMed: 26574669]


25. Hecht M, Kramer LM, von Arnim CAF, Otto M, Thal DR (2018) Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. *Acta Neuropathol* 135: 681–694 Doi 10.1007/s00401-018-1834-y [PubMed: 29574591]
26. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T (1993) Cerebral amyloid angiopathy: A significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. *Journal of the Neurological Sciences* 116: 135–141 Doi 10.1016/0022-510x(93)90317-r [PubMed: 8336159]
27. Keage HA, Carare RO, Friedland RP, Ince PG, Love S, Nicoll JA, Wharton SB, Weller RO, Brayne C (2009) Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. *BMC Neurol* 9: 3 Doi 10.1186/1471-2377-9-3 [PubMed: 19144113]
28. Kumar-Singh S (2008) Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. *Genes Brain Behav* 7 Suppl 1: 67–82 Doi 10.1111/j.1601-183X.2007.00380.x [PubMed: 18184371]
29. Lauer A, van Veluw SJ, William CM, Charidimou A, Roongpiboonsopit D, Vashkevich A, Ayres A, Martinez-Ramirez S, Gurol EM, Biessels GJet al. (2016) Microbleeds on MRI are associated with microinfarcts on autopsy in cerebral amyloid angiopathy. *Neurology* 87: 1488–1492 Doi 10.1212/WNL.0000000000003184 [PubMed: 27613583]
30. Leclercq PD, Murray LS, Smith C, Graham DI, Nicoll JA, Gentleman SM (2005) Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype. *J Neurol Neurosurg Psychiatry* 76: 229–233 Doi 10.1136/jnnp.2003.025528 [PubMed: 15654038]
31. Mamourian AC, Hoopes PJ, Lewis LD (2000) Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: an in vitro and animalmodel investigation. *AJNR Am J Neuroradiol* 21: 105–111 [PubMed: 10669233]
32. McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, Perl DP, Stein TD, Vonsattel JP, Stewart Wet al. (2016) The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathol* 131: 75–86 Doi 10.1007/s00401-015-1515-z [PubMed: 26667418]
33. McKee AC, Daneshvar DH, Alvarez VE, Stein TD (2014) The neuropathology of sport. *Acta Neuropathol* 127: 29–51 Doi 10.1007/s00401-013-1230-6 [PubMed: 24366527]
34. McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, Lee H-S, Hall G, Wojtowicz SM, Baugh CMet al. (2013) The spectrum of disease in chronic traumatic encephalopathy. *Brain* 136: 43–64 Doi 10.1093/brain/aws307 [PubMed: 23208308]
35. McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CMet al. (2013) The spectrum of disease in chronic traumatic encephalopathy. *Brain* 136: 43–64 Doi 10.1093/brain/aws307 [PubMed: 23208308]
36. Merlini M, Wanner D, Nitsch RM (2016) Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy. *Acta Neuropathol* 131: 737–752 Doi 10.1007/s00401-016-1560-2 [PubMed: 26988843]
37. Mez J, Solomon TM, Daneshvar DH, Murphy L, Kiernan PT, Montenegro PH, Kriegel J, Abdolmohammadi B, Fry B, Babcock KJet al. (2015) Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. *Alzheimers Res Ther* 7: 62 Doi 10.1186/s13195-015-0148-8 [PubMed: 26455775]
38. Montenegro PH, Alosco ML, Martin BM, Daneshvar DH, Mez J, Chaisson CE, Nowinski CJ, Au R, McKee AC, Cantu RCet al. (2017) Cumulative Head Impact Exposure Predicts Later-Life Depression, Apathy, Executive Dysfunction, and Cognitive Impairment in Former High School and College Football Players. *J Neurotrauma* 34: 328–340 Doi 10.1089/neu.2016.4413 [PubMed: 27029716]
39. Montenegro PH, Corp DT, Stein TD, Cantu RC, Stern RA (2015) Chronic traumatic encephalopathy: historical origins and current perspective. *Annu Rev Clin Psychol* 11: 309–330 Doi 10.1146/annurev-clinpsy-032814-112814 [PubMed: 25581233]
40. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SSet al. (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol* 123: 1–11 Doi 10.1007/s00401-011-0910-3 [PubMed: 22101365]



41. Nordstrom A, Nordstrom P (2018) Traumatic brain injury and the risk of dementia diagnosis: A nationwide cohort study. *PLoS Med* 15: e1002496 Doi 10.1371/journal.pmed.1002496 [PubMed: 29381704]
42. O'Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, Ikeda D, Greenberg SM (2000) Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. *N Engl J Med* 342: 240–245 Doi 10.1056/NEJM200001273420403 [PubMed: 10648765]
43. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ (2002) Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study. *Neurology* 58: 1629–1634 Doi 10.1212/wnl.58.11.1629 [PubMed: 12058090]
44. Rannikmae K, Kalaria RN, Greenberg SM, Chui HC, Schmitt FA, Samarasekera N, Al-Shahi Salman R, Sudlow CL (2014) APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. *J Neurol Neurosurg Psychiatry* 85: 300–305 Doi 10.1136/jnnp-2013-306485 [PubMed: 24163429]
45. Richard E, Carrano A, Hoozemans JJ, van Horssen J, van Haastert ES, Eurelings LS, de Vries HE, Thal DR, Eikelenboom P, van Gool WA et al (2010) Characteristics of dyschoric capillary cerebral amyloid angiopathy. *J Neuropathol Exp Neurol* 69: 1158–1167 Doi 10.1097/NEN.0b013e3181fab558 [PubMed: 20940625]
46. Russo MV, Latour LL, McGavern DB (2018) Distinct myeloid cell subsets promote meningeal remodeling and vascular repair after mild traumatic brain injury. *Nature Immunology* 19: 442–452 Doi 10.1038/s41590-018-0086-2 [PubMed: 29662169]
47. Scott G, Ramlackhansingh AF, Edison P, Hellyer P, Cole J, Veronese M, Leech R, Greenwood RJ, Turkheimer FE, Gentleman SM et al. (2016) Amyloid pathology and axonal injury after brain trauma. *Neurology* 86: 821–828 Doi 10.1212/WNL.0000000000002413 [PubMed: 26843562]
48. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C (2007) Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. *Brain* 130: 2310–2319 Doi 10.1093/brain/awm156 [PubMed: 17638859]
49. Stein TD, Alvarez VE, McKee AC (2014) Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. *Alzheimers Res Ther* 6: 4 Doi 10.1186/alzrt234 [PubMed: 24423082]
50. Stein TD, Montenegro PH, Alvarez VE, Xia W, Crary JF, Tripodis Y, Daneshvar DH, Mez J, Solomon T, Meng G et al. (2015) Beta-amyloid deposition in chronic traumatic encephalopathy. *Acta Neuropathol* 130: 21–34 Doi 10.1007/s00401-015-1435-y [PubMed: 25943889]
51. Tagge CA, Fisher AM, Minaeva OV, Gaudreau-Balderrama A, Moncaster JA, Zhang XL, Wojnarowicz MW, Casey N, Lu H, Kokiko-Cochran ON et al. (2018) Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. *Brain* 141: 422–458 Doi 10.1093/brain/awx350 [PubMed: 29360998]
52. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. *Acta Neuropathol* 120: 169–183 Doi 10.1007/s00401-010-0707-9 [PubMed: 20535486]
53. Tian J, Shi J, Bailey K, Mann DMA (2003) Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer's disease. *Neuroscience Letters* 352: 137–140 Doi 10.1016/j.neulet.2003.08.048 [PubMed: 14625042]
54. Tian J, Shi J, Bailey K, Mann DMA (2004) Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease. *Neuropathology and Applied Neurobiology* 30: 46–56 Doi doi:10.1046/j.0305-1846.2003.00510.x [PubMed: 14720176]
55. Vinters HV (1987) Cerebral amyloid angiopathy. A critical review. *Stroke* 18: 311–324 Doi 10.1161/01.str.18.2.311 [PubMed: 3551211]
56. Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. *Stroke* 14: 924–928 Doi 10.1161/01.str.14.6.924 [PubMed: 6658996]



57. Viswanathan A, Patel P, Rahman R, Nandigam RN, Kinnecom C, Bracoud L, Rosand J, Chabriat H, Greenberg SM, Smith EE (2008) Tissue microstructural changes are independently associated with cognitive impairment in cerebral amyloid angiopathy. *Stroke* 39: 1988–1992 Doi 10.1161/STROKEAHA.107.509091 [PubMed: 18436874]
58. Vonsattel JP, Del Amaya MP, Keller CE (2008) Twenty-first century brain banking. Processing brains for research: the Columbia University methods. *Acta Neuropathol* 115: 509–532 Doi 10.1007/s00401-007-0311-9 [PubMed: 17985145]
59. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. (1991) Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. *Ann Neurol* 30: 637–649 Doi 10.1002/ana.410300503 [PubMed: 1763890]
60. Walt GS, Burris HM, Brady CB, Spencer KR, Alvarez VE, Huber BR, Guilderson L, Abdul Rauf N, Collins D, Singh Tet al. (2018) Chronic Traumatic Encephalopathy Within an Amyotrophic Lateral Sclerosis Brain Bank Cohort. *J Neuropathol Exp Neurol* 77: 1091–1100 Doi 10.1093/jnen/nly092 [PubMed: 30299493]
61. Weissberg I, Veksler R, Kamintsky L, Saar-Ashkenazy R, Milikovsky DZ, Shelef I, Friedman A (2014) Imaging blood-brain barrier dysfunction in football players. *JAMA Neurol* 71: 1453–1455 Doi 10.1001/jamaneurol.2014.2682 [PubMed: 25383774]
62. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. *Brain Pathol* 18: 253–266 Doi 10.1111/j.1750-3639.2008.00133.x [PubMed: 18363936]
63. Xiong L, Boulouis G, Charidimou A, Roongpiboonsopit D, Jessel MJ, Pasi M, Reijmer YD, Fotiadis P, Ayres A, Merrill E et al. (2018) Dementia incidence and predictors in cerebral amyloid angiopathy patients without intracerebral hemorrhage. *J Cereb Blood Flow Metab* 38: 241–249 Doi 10.1177/0271678X17700435 [PubMed: 28318355]



**Figure 1: Distribution of cerebral amyloid angiopathy by hierarchical cluster algorithm.**  
**a)** An unbiased hierarchical cluster heatmap shows the distribution and severity of CAA in all participants with CAA and without missing data (n=222). The orange color scale indicates the semi-quantitative severity of CAA (0-3). The four major clusters are indicated by the shaded gray bars to the right of the dendrogram. Pathologic diagnoses are shown in the adjacent green (No AD/CTE), blue (AD), red (CTE), and black (AD & CTE) colored column and in panel C. **b)** The mean severity of CAA across all regions is shown for each cluster in both the leptomeningeal (red) and cortical (blue) vessel compartments. Analysis of the clusters using a mixed linear mixed effects model showed that cluster 2 had significantly more severe disease in the leptomeninges across all regions compared to the cortex (\*\*p < 0.001). Cluster 4 and cluster 1 also showed significant differences (\*p=0.001) but had much smaller mean differences than cluster 2. **c)** The composition of the clusters differed significantly by pathology (p<0.001;  $\chi^2$  analysis). The proportion of individuals with CTE was significantly higher in Cluster 2 compared to cluster 1 and cluster 4 (p < 0.001). Cluster 1 and cluster 4 had a significantly higher percentage of individuals with AD than cluster 2 (p < 0.001). There was no difference in the proportion of No CTE/No AD individuals


throughout the clusters and the only significant difference in CTE & AD individuals was between clusters 1 and 3 ( $p < 0.001$ ).

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



**Figure 2: Distribution of CAA by pathology group.**

**a)** Participants with AD had a significantly increased frequency of CAA in the parietal lobe in both the cortex and the leptomeninges as compared to the frontal lobe. In contrast, participants with CTE had increased CAA frequency in the leptomeninges in both the frontal and parietal lobes compared to the cortex; \* $p < 0.05$ , \*\*\* $p < 0.001$ ,  $\chi^2$  tests, **b)** Participants with AD had increased CAA severity in the parietal lobe (including in both the cortex and leptomeninges) compared to the frontal lobe compartments. In contrast, participants with CTE had increased CAA severity in the leptomeninges of the frontal lobe compared to the frontal or parietal cortices. **c)** CAA severity was significantly increased in the frontal lobe of participants with CTE compared to AD in the leptomeninges ( $p < 0.001$ ) and trended towards increased CAA in the frontal cortex ( $p = 0.052$ ). **d)** CAA severity was significantly increased in the leptomeninges of participants with CTE compared to those with AD in both the frontal and the parietal lobes ( $p$ 's = 0.002). For b-d, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , ANOVA with Holm-Sidak correction for multiple comparisons.



**Figure 3: CAA was associated with altered Aβ, sulcal tau pathology, and synaptic density.** Aβ<sub>1-40</sub>, Aβ<sub>1-42</sub>, tau pathology (AT8 density), and PSD-95, a marker of synaptic density, were measured by immunoassay in the dorsolateral frontal cortex, and age-adjusted means are shown, **a**) Multiple comparison testing (Holm-Sidak) showed that Aβ<sub>1-40</sub> was significantly increased in those with CTE and CAA compared to only CTE. **b**) Aβ<sub>1-42</sub> was significantly increased in those with CTE and CAA and in those without CTE or AD. **c**) Tau pathology as measured by AT8 density was significantly increased within the sulcal depth in participants with CTE and CAA compared to those with CTE alone. **d**) CAA was associated with a significant decrease in the age adjusted means of PSD-95 density in participants without CTE or AD as well as in those with CTE. Age-adjusted means with standard error are shown (\*p < 0.05, \*\*\*p < 0.001, ANOVA with Holm-Sidak correction for multiple comparisons).

**Table 1:**  
Demographic, clinical, and pathological measures between pathology groups

	No CTE/No AD	AD	CTE	CTE & AD	p-value
<b>Sample size (n)</b>	282	230	251	44	
<b>Cohort</b>					<0.001 <sup>*</sup>
FHS	137 (48.6%)	70 (30.4%)	0 (0%)	2 (4.5%)	<0.05 <sup>a,b,c,d,e,f</sup>
UNITE	66 (23.4%)	5 (2.2%)	246 (98.0%)	40 (90.9%)	<0.05 <sup>a,b,c,d,e</sup>
BUADC	79 (28.0%)	155 (67.4%)	5 (2.0%)	2 (4.5%)	<0.05 <sup>a,b,c,d,e</sup>
<b>Age at death (S.E.M)</b>	74.6 (1.5)	84.3 (0.7)	59.7 (1.2)	75.5 (1.7)	<0.001 <sup>#,a,b,d,e,f</sup>
<b>Sex %male</b>	176/106 (62.4%)	135/95 (58.7%)	251/0 (100%)	43/1 (97.7%)	<0.001 <sup>*b,c,d,e</sup>
<b>RHI y/n (%exposed)</b>	76/92 (45.2%)	13/54 (19.4%)	249/0 (100%)	44/0 (100%)	<0.001 <sup>*a,b,c,d,e</sup>
Exposure years (S.E.M.)	4.12 (0.51)	1.58 (0.50)	16.1 (0.4)	15.9 (1.4)	<0.001 <sup>#a,b,c,d,e</sup>
<b>CAA with/without (% with)</b>	153/129 (54.3%)	220/10 (95.7%)	72/179 (28.7%)	36/8 (81.8%)	<0.001 <sup>*a,b,c,d,e,f</sup>
<b>CAA severity score n (%)</b>					<0.001 <sup>*</sup>
1	98 (64.1%)	86 (39.1%)	49 (68.1%)	13 (36.1%)	<0.05 <sup>a,c,d,f</sup>
2	44 (28.8%)	84 (38.2%)	15 (20.8%)	15 (41.7%)	<0.05 <sup>d</sup>
3	11 (7.2%)	50 (22.7%)	8 (11.1%)	8 (22.2%)	<0.05 <sup>a,c</sup>
<b>CTE stage % (n)</b>					<0.001 <sup>*</sup>
Stage I			37 (14.7%)	3 (6.8%)	
Stage II			54 (21.5%)	4 (9.1%)	
Stage III			97 (38.6%)	11 (25.0%)	
Stage IV			63 (25.1%)	26 (59.1%)	<0.05 <sup>f</sup>
<b>Neocortical LBD</b>	20/262 (7.1%)	33/197 (14.3%)	13/238 (5.2%)	6/38 (13.6%)	0.002 <sup>*a,d</sup>
<b>Remote cortical microinfarcts</b>	74/173 (30.0%)	62/149 (29.4%)	28/189 (12.9%)	7/29 (19.4%)	<0.001 <sup>*b,d</sup>
<b>Macro hemorrhages</b>	3/235 (1.3%)	0/203 (0%)	5/195 (2.5%)	1/33 (2.9%)	0.139 <sup>*</sup>
<b>Dementia</b>	73/157 (31.7%)	172/18 (90.5%)	123/109 (53.0%)	36/2 (94.7%)	<0.001 <sup>*a,b,c,d,f</sup>

Data are presented as mean (S.E.M.) years for age at death and contact sports exposure and as # yes/# no (%) unless otherwise indicated. AD: Alzheimer disease; CTE: chronic traumatic encephalopathy; LBD: Lewy body disease; RHI: repetitive head impacts;

# ANOVA with Bonferroni correction,

\*  $\chi^2$  test for proportions between all pathology groups,

<sup>a</sup> p<0.05 for comparison between No CTE/No AD and AD,

<sup>b</sup> p<0.05 for comparison between No CTE/No AD and CTE,

<sup>c</sup> p<0.05 for comparison between No CTE/No AD and CTE & AD,

<sup>d</sup> p<0.05 for comparison between AD and CTE,

<sup>e</sup> p<0.05 for comparison between AD and CTE & AD,



<sup>f</sup>  
p<0.05 for comparison between CTE and CTE & AD

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2:**

Clinical and exposure measures between clusters

Cluster	1	2	3	4	p-value
<b>Sample Size (n)</b>	164	11	28	19	
<b>Age at Death (S.E.M)</b>	84.7 (1.0)	72.5 (3.3)	82.4 (2.2)	84.7 (2.5)	<0.001 <sup>*a,e</sup>
<b>Gender m/f (%male)</b>	89/73 (54.9%)	10/1 (83.3%)	19/9 (67.9%)	13/6 (68.4%)	0.062
<b>Pathology Group (n)</b>					<0.001
No CTE/No AD	65 (39.6%)	4 (36.4%)	6 (21.4%)	2 (10.5%)	
AD	66 (40.2%)	0 (0%)	12 (42.9%)	12 (63.2%)	<0.05 <sup>*a,e</sup>
CTE	24 (14.6%)	5 (45.5%)	2 (7.1%)	2 (10.5%)	<0.05 <sup>*a,d</sup>
CTE & AD	9 (5.5%)	2 (18.2%)	8 (28.6%)	3 (15.8%)	<0.05 <sup>*b</sup>
<b>RHI y/n (%)</b>	42/79 (34.7%)	10/0 (100%)	12/7 (63.2%)	8/4 (66.7%)	<0.001 <sup>*a</sup>
Exposure years	5.4 (0.8)	16.7 (2.0)	7.6 (1.8)	7.9 (0.7)	
<b>LBD y/n (%)</b>	52/112 (31.7%)	3/8 (27.3%)	12/16 (42.9%)	4/15 (21.1%)	0.443
<b>CTE y/n (%)</b>	33/131 (20.1%)	7/4 (63.6%)	10/18 (35.7%)	5/13 (26.3%)	<0.001 <sup>*a</sup>
Stage I	1 (3%)	0 (0%)	1 (10%)	0 (0%)	
Stage II	3 (9.1%)	2 (28.6%)	0 (0%)	0 (0%)	
Stage III	16 (48.5%)	2 (28.6%)	2 (20%)	1 (20%)	
Stage IV	13 (39.4%)	3 (42.9%)	7 (70%)	4 (80%)	
<b>Dementia</b>	99/54 (64.7%)	8/3 (72.7%)	21/6 (77.8%)	16/3 (84.2%)	0.224

Participants with complete CAA data in all brain regions were used in hierarchical clustering analysis (n=222). Values are presented as mean (S.E.M.) years for age at death and contact sports exposure; mean years of exposure are for subjects with sports exposure >0; AD: Alzheimer disease; CTE: chronic traumatic encephalopathy; LBD: Lewy body disease; RHI, repetitive head impacts;

\*  $\chi^2$  test for proportions,

<sup>a</sup> p<0.05 for comparison between clusters 1 and 2,

<sup>b</sup> p<0.05 for comparison between clusters 1 and 3,

<sup>c</sup> p<0.05 for comparison between 1 and 4,

<sup>d</sup> p<0.05 for comparison between clusters 2 and 3,

<sup>e</sup> p<0.05 for comparison between clusters 2 and 4.

**Table 3:**

History of contact sports participation predicts increased severity of CAA in frontal leptomeninges

	Severity of CAA n=143		
	OR	95% CI	p-value
Contact sports participation (y/n)	4.01	2.52-6.38	<0.001

Weighted cumulative logit proportional odds regression analysis was performed in participants with CAA > 0 for CAA severity outcome (odds for an increase in severity score 1-3), adjusting for propensity score matching participants by age, AD, and APOE ε4 status.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 4:**

CAA was an independent predictor of dementia

	n=690		
	OR	(95% CI)	p-value
AD	10.8	(6.1-19.2)	< <b>0.001</b>
LBD, neocortical	7.73	(2.55-23.4)	< <b>0.001</b>
CTE stage	1.70	(1.44-2.00)	< <b>0.001</b>
CAA	1.75	(1.02-2.99)	<b>0.043</b>

CTE: Chronic traumatic encephalopathy (stage 0-IV); AD: Alzheimer disease; LBD: Lewy body disease, neocortical type; CAA: Cerebral amyloid angiopathy severe (severity score 2-3). Logistic regression was performed adjusting for age, sex, and cohort.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript